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Introduction
At the 71st World Health Assembly in Geneva in May 2018, a 
political alliance was struck between Chris Murray, Director 
of the Institute for Health Metrics and Evaluation (IHME), 
and Tedros Adhanom Ghebreyesus, Director-General of the 
World Health Organisation (WHO). IHME and WHO signed a 
Memorandum of Understanding (MOU), ending what Lancet 
editor-in-chief Richard Horton called “a Cold War” that had 
simmered and occasionally erupted between the two organisa-
tions since IHME was established in 20071. Since IHME started 
putting out the results of its Global Burden of Disease (GBD) 
study in 20122,3, there have been controversial differences 
between IHME’s estimates of disease burden and those of 
WHO4,5, particularly around malaria6, tuberculosis7, causes of 
child death8,9, and maternal mortality10.
The explicit agreement by IHME and WHO to produce a 
single GBD study—“a series of capstone papers summarizing 
high-level findings would be published in The Lancet11” 
before being used in official WHO documents—raises important 
questions about what an alliance of global burden of disease 
estimates means for global health governance and health policy 
in the Global South. In official language, these estimates’ 
producers have always meant them to go hand in hand with 
the development of better data collection and vital regis-
tration systems in countries with limited data collection 
infrastructure12,13. In the 2018 MOU itself, in fact, both WHO and 
IHME assert that “estimates are no replacement for data from 
strong surveillance systems11.” In reality, producing burden of 
disease estimates has always required the WHO to reconcile 
the differences between its own disease estimates and country 
reported numbers. With this new alliance, the organisation 
will also have to reconcile estimates and methodologies from 
IHME with its own estimates and country reported numbers. 
These acts of reconciliation are mirrored by the attempted 
alliance between the World Bank and IHME to produce the 
Human Capital Index and the methodological tensions revealed 
between the two organisations with regards to the use of global 
disease burden estimates14.
The practice of estimation in health development is by no means 
new. Early examples of the use of mathematical models based 
on assumptions include Daniel Bernoulli’s 1766 predictions of 
smallpox morbidity and mortality rates, should the English 
government not take on inoculation practices15,16. However, as 
has been remarked by many scholars17, the amount of money and 
labour that went into estimation-production radically increased 
in the era of the Millennium Development Goals and is expected 
to grow in the era of measuring the progress of the much 
more complicated Sustainable Development Goals. This includes 
IHME’s production of the SDG-index, which was created 
particularly with the aim to assess the SDGs’ measurability18.
In this article, we present first a summary of the origins and 
evolution of the GBD, which has been the object of much 
scrutiny19, over the past 25 years. Then, we analyse two illustra-
tive examples of GBD estimates and the ways in which they gloss 
over the assumptions and knowledge gaps in their production, 
highlighting the importance of historical context by country 
and by disease in the quality of health data. We show how these 
estimates gloss over their assumptions and knowledge gaps, 
attempting to quantify context and data quality. Finally, we 
delve into the question of the end users of these estimates. Who 
uses these estimates and who does not, and what tensions lie at 
the heart of producing estimates of local, national, and global 
burdens of disease? These tensions bring to light the different 
institutional ethics and motivations of IHME, WHO, and the 
World Bank, and draw our attention to how the production of 
data and estimates is key to representing problems and their 
solutions in global health. With the rise in investment and power 
of global health estimates, the question of representing global 
health problems becomes even more entangled in decisions 
made about how to adjust reported numbers and statistical 
equations. The tensions at the heart of the GBD study are of 
utmost importance because those who represent global health 
problems are those who determine how money and influence 
flows to address them.
Methods
This paper relies on two data sources. First, we used published 
articles to construct a timeline of the history and methodo-
logical conflicts of the global burden of disease study. Second, 
we analysed popular media representations of partnerships 
between WHO, IHME, and the World Bank, as well as field 
notes taken by M.T. at three public events at IHME and the 
World Bank. These three events were IHME’s 20th Global 
Burden of Disease Anniversary event in September 2017, IHME’s 
Annual Board Meeting in June 2018, and Sir George Alleyne’s 
lecture on human capital at the World Bank headquarters in 
July 2018.
The 25 years of the Global Burden of Disease study
The GBD and the disability-adjusted life year (DALY) have 
been subject to detailed scrutiny since their inception in the early 
1990s. The DALY and the GBD first came onto the world 
scene out of a partnership between Chris Murray, Alan Lopez, 
and Dean Jamisona, with the explicit institutional support of the 
World Bank. The Bank requested “a comparative, comprehen-
sive, and detailed study of health loss worldwide to provide 
the basis for objective assessments about the probable benefits 
of applying packages of interventions20,” as part of the Bank’s 
increasing influence and financial investment in international 
health development in the 1980s and early 1990s21. The team’s 
work culminated in the publication of the 1993 World Develop-
ment Report (WDR), Investing in Health, which synthesized 
decades of work in health economics into the new health metric, 
the DALY, to provide punchy, useable language for justifying 
public and private, national and international investment in 
health. Murray and Lopez themselves define the study as a 
“systematic scientific effort to quantify the comparative magnitude 
of health loss from diseases, injuries, and risks by age, sex, and 
population over time20”.
aThese three individuals are listed a key three among many others whose labour 
were essential to the process of producing and disseminating the global burden 
of disease study.
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The three explicitly stated aims of the GBD were “(i) to decou-
ple epidemiological assessment of the magnitude of health 
problems from advocacy by interest groups of particular health 
policies or interventions; (ii) to include in international health 
policy debates information on non-fatal health outcomes along 
with information on mortality; and (iii) to undertake the quan-
tification of health problems in units that can also be used in 
economic appraisal22”. The study’s architects were motivated 
by providing estimates on morbidity rates, as well as mortality 
rates, on diseases and conditions from a neutral, objective 
perspective. These estimates were built to be plugged into 
economic appraisal calculations to give international health 
organisations and governments guidance for prioritising health 
interventions based on economic reasoning. Until that point, 
assessments of global disease morbidity and mortality rates 
had been the responsibility of different programmes at WHO 
that focused only on specific diseases and interested largely 
with mortality rates, with estimates that leant heavily toward 
overestimation23. The DALY, as a metric which quantified 
morbidity over time, was introduced as a means of drawing 
global attention to diseases and injuries that burdened populations 
but did not always result in death.
For all future GBD studies, 1990 served as the benchmark 
year, and the disease data from that year would be reworked in 
multiple different ways over the next 25 years. The next big 
moment for the GBD was 1997, when Richard Horton at 
The Lancet published the first peer-reviewed series of articles 
based on the research that was at the heart of the 1993 WDR, 
which Murray and Lopez call the “first complete revision of the 
GBD 1990 study20.” The publication of these four articles12,24–26 
in The Lancet was so foundational to the genesis of the GBD 
that it served as the starting point for IHME’s 20th anniversary 
celebration of the event in Seattle in 2017. Still using the year 
1990, these articles addressed a few of the major concerns that 
scholars had identified in the original study published in 1993, 
including the criticism of the way the study weighted DALYs 
by age27. The DALY quantifies healthy time lost to illness or 
death against a standardised average healthy life expectation, by 
combining years of life lost to death (YLL) and years of life 
lost to disability (YLD). In each cycle of the GBD since, its 
architects have carefully reassessed the nature of the disability 
weights used to condition DALYs, among other changes over the 
decades (Table 1).
By 2000, Chris Murray had joined Alan Lopez at WHO, and they 
published their national health systems ranking using the GBD 
and the DALY, with the explicit institutional support of WHO. 
They had the particular support of Gro Harlem Brundtland and 
Julio Frenk, who were, respectively, Director-General of WHO 
and executive director of the Evidence and Information for Policy 
cluster at the time. This resulted in the publication of the 2000 
World Health Report, Health Systems: Improving Performance. 
This exercise in explicitly naming and shaming countries for 
the performance of their health systems was highly controver-
sial, as those countries that scored lower expressed their dis-
pleasure to WHO and as researchers and popular media pointed 
alternatively to WHO’s “underlying pro-market ideology28,29” 
and its “Marxist stance29,30.” However, as public health scholar 
Martin McKee argued, the 2000 WHR did in fact “place [the] 
assessment of health system performance firmly on the political 
and research agendas29”. For the years 1999–2002 and 2004, 
WHO produced multiple GBD updates and published the esti-
mates largely in the intervening World Health Reports31–34. 
These were borne out of the Global Programme on Evidence 
for Health Policy within WHO, part of the Evidence and 
Information for Policy cluster of which Murray became execu-
tive director when Frenk left to become the Mexican Minister 
of Health in the summer of 2000.
When Brundtland resigned from WHO in 2003, the GBD lost 
its most powerful supporter in the organisation, which led to 
the split between GBD studies, marked by Murray’s departure 
from WHO for Harvard University in 2003. In 2007, the Bill and 
Melinda Gates Foundation (BMFG), along with the University 
of Washington, funded Murray and Lopez to create an inde-
pendent, scientific institution to produce estimates of global 
disease burden35. Part of Murray and Lopez’s vision was to 
separate the production of estimates from the politics of vertical 
approaches and disease advocacy at WHO23. IHME’s found-
ing board members included Brundtland, Frenk, and Tedros. 
Given their large global health portfolio, BMFG also had a clear 
interest in ensuring timely, independent, and robust produc-
tion of burden of diseases estimates, and IHME became their 
guide to do this. IHME lists impartiality as one of its five core 
principles: “For health evidence to be useful, it also must be 
credible, generated by a scientific process unimpeded by 
political, financial, or other types of interference. IHME was 
created to fill a gap in global health: to separate the measure-
ment and evaluation of health policies and programs from the 
process of creating, implementing, and advocating for policies 
and programs36”.
In 2012, the group published their first GBD study in The Lancet, 
covering the years 1990, 2005, and 2010, calling it the GBD 
201037. As we will touch on more extensively in the next 
section, this study caused a stir in the global health community, 
as some crucial estimates, like those of malaria morbidity and 
maternal mortality, diverged heavily from those put out by WHO 
and its UN agency partners for the same year38. In 2015, IHME 
published the revamped GBD 2013 in The Lancet, including 
estimates for all of the years between 1990–2013, and since 
2016, they have published complete annual reassessments of 
these years’ estimates, adding new assessments in each cycle. 
IHME’s GBD 2017 was published in The Lancet in November 
2018.
The DALY, the metric at the heart of the GBD, was introduced 
explicitly as a means to draw global attention to diseases that 
do not only kill but also disable. By quantifying the loss of 
healthy years, the DALY was meant to unveil suffering, like 
lower back pain or depression, that weighs heavy on the world. 
Some scholars have argued that the metric, so ready to be used 
for cost-benefit analysis, and its proliferation more fundamentally 
have contributed to an intensification of economic rationality in 
and the neoliberalisation of global health thinking39,40. Medical 
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anthropologist Vincanne Adams argues that “the DALY provides 
an economic measure of human productive value by calculating 
loss of productivity due to disease or disability42”. As a tool that 
was created for the World Bank’s new increased investment in 
global health development, the DALY has from the start tied 
economic values to human suffering and attempts to alleviate 
it43. Explicitly meant to be useable for ministers of finance and 
drawing a particular American version of economics into the 
sphere of health development, the DALY has led to the reign of 
health economics in global health governance, a recent shift 
which Sridhar calls the economic gaze44.
On the production of the global burden of disease
One of the key challenges in producing a complete picture of the 
world’s health has been the lack of adequate civil registration 
and vital statistics systems or health information systems in 
several countries and the need to use a limited dataset to estimate 
global burden of disease37. This has resulted in a proliferation 
of modelling an estimation of the larger picture, according to 
the data available. Inherent in producing estimates of population 
health is the question of how comfortable estimate producers 
are with extrapolating robust-seeming estimates from little or 
no data. “Imputing” data, in statistics parlance and the global 
health context, means bridging over conceived gaps in available 
data in one country with estimates based on data that does exist 
in comparable countries, often defined as comparable in terms 
of levels of GDP and regional proximity. This allows IHME, for 
example, to have estimates of malaria morbidity in the Central 
African Republic, where disease surveillance work has been 
incomplete since civil wars broke out in 201245. Estimates’ 
level of uncertainty is directly related to the presence of health 
data infrastructure, meaning that estimates are least robust for 
countries with weaker health systems, which are often those 
countries perceived as needing disease burden estimates the 
most. Since one of IHME’s fundamental principles is that “[too] 
often, no estimate of a problem is interpreted as an estimate 
of no problem20”, the organisation is known to be much more 
comfortable with imputation than the global health organisa-
tions that often use its data such as the World Bank, WHO and 
UNICEF.
However, imputing is not exclusively the practice of IHME. 
Various WHO, World Bank, and multilateral partnership 
programmes also practice imputation and other forms of data 
correction. While it is widely used, disagreements lie in the 
degree to which various organisations are comfortable with 
using imputation. Imputation and data correction can lead to 
tension between various producers of global health estimates, 
as well as between estimate producers and country officials. 
When the estimates of global disease and injury burden are 
used by other organisations or in health policy, they do not 
carry with them the complex methodologies nor the underlying 
primary data from country level involved in their creation. 
Discrepancies between the IHME and WHO (and other UN 
agencies) sets of estimates have the effect of both reminding 
users of the complexities behind them, while also promoting 
confusion for health policy makers17. Even without having to 
address the discrepancies between its estimates and IHME’s, 
WHO has had to reconcile its own official estimates and 
country-reported morbidity and mortality rates. In its produc-
tion of global and national health estimates, WHO uses multiple 
sources of data, although not as many as IHME, including 
Demographic Household Surveys (DHS) and the World Health 
Survey, to round out data provided through administratively 
reported data in public health clinics, in order to address 
potential bias within such production systems. As a result, WHO 
estimates can often be quite different than those that health 
ministers and finance ministers gather from their own statistics 
offices, and when global health estimates diverge dramatically 
from nationally gathered numbers, health ministers unsurpris-
ingly mistrust them17.
Furthermore, on the scale of global health estimates themselves, 
one of the most controversial discrepancies between IHME’s 
and UN agencies’ estimates, as well as with nationally reported 
numbers, are those of malaria mortality rates6. In 2010, IHME 
reported 1,238,000 deaths due to malaria, and that 524,000 of 
those were amongst individuals five years or older2. For the 
same year, WHO reported 655,000 deaths in total with approxi-
mately 91,700 of those amongst individuals five years or older46. 
This is due partly to the problem of a lack of information and 
diagnostic capacity in many places where malaria is endemic, 
but it is also due to discrepancies in defining the presence of 
malaria and the causality of a death. Since decreasing malaria 
morbidity and mortality was an explicit part of the Millennium 
Development Goals and the global health fight against malaria 
is heavily funded, this discrepancy caused a tumult in the global 
health world, which had three years to go to meet the Goals47. 
The techniques for producing global level estimates of malaria 
mortality are particularly complicated because the presence 
of malaria parasites in the blood is not a determination for 
mortality due to the disease, as the parasite is often present in 
populations where the disease is endemic without it causing 
sickness or death to individuals. Because IHME used estima-
tions of parasite density produced by the Malaria Atlas Program 
in the process of determining malaria mortality, their estimates 
carry with them certain assumptions about the presence of 
malaria that is possibly influenced by the Gates Foundation’s 
political investment in the eradication of the disease.
Another notable discrepancy between the two sets of estimates 
is that of maternal mortality rates (MMR)10,48. In 2010, four UN 
agencies—UNICEF, UNFPA, the World Bank, and WHO— 
produced MMR estimates for the time period of 1990–200849, 
while IHME produced estimates for the time period of 
1980–200850. For the final year of the study, 2008, the differ-
ence between the two estimates was low: IHME estimated 
342,900 maternal deaths compared with the UN agencies’ 
estimate of 358,000. However, the two estimates differed 
markedly on their 1990 estimates, which changed the degree of 
global decrease in maternal deaths10. As estimates are used by 
global health organisations and putatively for country-level 
health policy makers to measure success of certain kinds of 
interventions or approaches to health problems, differences in 
change certainly confound attempts to distinguish failing or 
successful health campaigns.
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The fact of the matter is that the production of these estimates 
is conditioned by many levels of assumption, and they can 
result in numbers that are unrecognizable at the local level. In 
anthropologist-physician Clare Wendland’s analysis of maternal 
mortality ratio production and maternal care in a hospital in 
Malawi, she was confronted by health workers who expressed 
shock at the estimates produced far away that were being used 
to define MMR in the country: “They are saying we will meet 
the Millennium Development Goals. But I can’t believe it. If it’s 
that low, why are we still seeing this [much public mourning] 
every day?51” Additionally, the availability and quality of 
local empirical data that serves as a starting point for these 
estimates are often determined by global health organisation’s 
priorities. Data collection systems may be thrown up around 
certain issues in conditions of precarity or where no problem 
was perceived before, such as cholera rates in post-disaster Haiti, 
malaria and HIV rates that were collected despite data reten-
tion strikes in Senegal52, and Zika across the Americas in the 
wake of it being defined an epidemic by WHO53,54. What data is 
produced is defined by political and societal priorities and what 
types of data collection systems are funded by donors. This 
problem on the level of collecting empirical data becomes 
part of the larger political entanglements of the global health 
estimates they are used to produce.
Who uses these estimates?
The significant investment in disease burden estimates raises 
the question of who uses these estimates and how they are con-
sumed. Tracking the use of its studies has proven difficult for 
IHME itself, which relies on following citation data, tracking 
the use of its data visualization tools, feedback from its 
collaborative network, and overseeing awards like its Roux 
Prize, to determine who and which agencies have used its data. 
From these sources, we can see that their data is used by other 
academic researchers (i.e., a high number of citations), global 
health organisations (i.e., the use of GBD estimates in policy 
reports), and, to a lesser degree, ministers of health and local 
politicians (i.e., the use of GBD estimates in national and 
subnational health policy). Organisations like WHO and the 
World Bank have at times used IHME’s data and at other times 
produced their own. The most direct consumer of this data is the 
Gates Foundation itself, the largest funder of IHME, which has 
mandated that the group produce a yearly revamp of their GBD 
study55. The justification given is that BMGF uses IHME data 
to inform its investment portfolio. Since the organisation does 
not make its funding justification public, it is unclear how much 
GBD data is used regularly within BMGF to inform its funding 
portfolio.
In terms of WHO, the 2018 IHME-WHO Memorandum of 
Understanding is the second of its kind, the first having been 
signed in 2015. According to Boerma and Mathers, the first 
memorandum was signed “to encourage collaboration on 
country capacity strengthening, data sharing, and interaction on 
methods, tools, and actual global health estimates56”. When 
Dr. Tedros, who was on IHME’s founding board in 2007 as noted 
above, became WHO’s Director-General in 2016, he expressed 
his interest in reconciling the two systems of estimation. In the 
2018 MOU, IHME and WHO carefully outline how the two 
organisations would collaborate on the General Programme of 
Work 2019–2023 (GPW 13), in policy dialogue and country 
capacity building, in publications, and specifically on the produc-
tion of a single Global Burden of Disease study, the explanation 
of which occupies most of the document11. The agreement will 
require IHME and UN agencies to confront the methodological 
tensions at the heart of their differing approaches. Whether 
it will result in a more careful approach to global health esti-
mates, more explicitly communicating uncertainty and address-
ing ethical issues at the heart of the study is a question yet 
to be answered17. The GBD alliance will potentially create a 
global health data monopoly, extending the already extensive 
reach of the BMGF further into the WHO in determining how 
global health problems are known and what kinds of approaches 
to health problems are viable.
In its continued relationship with the World Bank, IHME 
has been most recently tied to the Human Capital Project. In 
October 2017 at Columbia University, World Bank President 
Jim Kim formally announced the Human Capital Project, after 
first presenting on it at the 20th GBD Anniversary event at IHME. 
He explained how the World Bank would publish the next 
generation of the health systems ranking from the 2000 World 
Health Report in Fall 2018, in partnership with IHME. The 
Human Capital Index would measure the educational attain-
ment, educational quality, and functional health levels of each 
country57. In his 2017 presentation at IHME, he argued for the 
inclusion of estimates from IHME’s GBD study in the proxy for 
functional health levels of each country. The goal of this new 
index was to measure countries’ investments in the education 
and health of its own citizenry. The larger human capital 
debate, of which the development of the DALY is a part, is a 
theoretical argument that economists have put forward to 
argue that education, health, and other social services are not 
expenditures but investments in a country’s economy58. As Flabbi 
and Gatti explain, when Gary Becker first introduced the idea 
that “investing in human capital is akin to investing in physical 
capital,” it was quite controversial59,60. Even when the 1993 
World Development Report61 was released, which leans heavily 
on the human capital argument, there was push back from 
mainstream economists, as the Senior Director of the Health, 
Nutrition, and Population team, Tim Evans, reminded the 
audience at a talk on human capital at the World Bank in July 
2018.
However, the execution of the Bank’s Human Capital Index 
project has resulted instead in two separate methodologies of 
estimating human capital, one produced by IHME and one by the 
World Bank14,62. This is a reversal of Bank President Jim Kim’s 
earlier assertion about forging a partnership between the two 
organisations. At the July 2018 talk on human capital at the 
World Bank, a team member of the Bank’s Human Capital Index 
project was asked why they were not taking advantage of 
IHME data and the “visibility” of the GBD and DALYs in their 
calculation and ranking of countries’ investment and status of 
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education and health. The team member argued that both the 
WHO and IHME versions of the GBD used higher levels of 
imputation than his team habitually used. He acknowledged 
that they did go first to the IHME data, but quickly realized that 
there were many parts of the estimates that were based off of 
scarce empirical data. For the Bank team, this was problematic 
for three reasons. First, imputing data meant losing the line of 
sight for ministers of finance, ministers of health, ministers of 
education. World Bank staff would not be able to remind minis-
ters of which study was used to produce them nor the history 
and context of the numbers referenced, and thus it would not be 
recognizable on the country level. Second, Bank staff would 
then lose the platform for advocating for better data collection 
and the importance of addressing the structural problems and 
inequities that exist beneath the data gaps. Finally, tracking 
progress on these indicators then becomes very complicated, 
as estimates change year to year also due to changes in estima-
tion or statistical science in addition to changes in material 
conditions. As Boerma and his colleagues remind us, “Neither 
country policy makers nor the global development community 
are best served by a global flood of health estimates derived 
from complex models as investments in country data collection, 
analytical capacity, and use are lagging56”.
Beyond those critiques, a central value of the GBD can be found 
precisely in its ability to compare countries and regions in the 
context of health development. In the 2018 IHME-WHO MOU, 
they argue that the “GBD’s utility is largely for comparisons 
across locations and over time”11. It is precisely this demand 
for comparability that calls for and allows for the standardiza-
tion of health data and the filling of data gaps17,42. However, it is 
worth asking the question of why global comparability is so 
important to achieving global health goals. The argument is that 
this work of comparing promotes healthy competition between 
countries, spurring those who see themselves as lagging behind 
into action, as global health leader Sir George Alleyne put it at 
a talk he gave on the World Bank’s Human Capital Project in 
July 2018. He added that there is something inherently human 
about thinking about the world in the framework of hierarchies 
and that statistics have long contributed to how we determine 
rank in such hierarchies. It is this assumption about the nature 
of competition that has prompted projects like the Human 
Capital Project, of course, and also the 2000 World Health 
Systems ranking.
In the quantification and rationalization of uncertainty, in an 
attempt to eradicate it, do other forms of evidence become 
delegitimized that are important in the process of determining 
health policy priorities? What are the larger ramifications of 
practices of standardization, data correction, and imputation 
that are performed particularly with the goal of making local 
contexts readable from a satellite’s view of the world? We would 
argue that it is certainly up for debate whether humans are 
doomed to be dominated by the work of competition rather 
than collaboration, and that there is an explicit history to 
the active construction and reification through statistics of 
“scientific” conceptions of hierarchies that benefit those who are 
at the top63,64.
Conclusion
Fundamentally, the production of the GBD and its centrality 
to global health governance raises the question of the larger 
effects of producing numerical assessments of disease burden 
“from a distance65”. How data is collected and how estimates 
are produced actually shape how we understand global health 
problems and their potential solutions, and thus estimates should 
never be taken for granted. When health workers, health policy 
makers, or even patients do not recognize their experiences in 
these estimates, like the Malawian physician mentioned above, 
the usefulness of such estimates and the kinds of knowledge 
with which they must be accompanied should be assessed. 
These estimates carry with them particular assumptions about 
the nature of illness and economics that attempt to universalize 
experiences of suffering and its impacts on our lives. They are 
excellent advocacy tools, but unfortunately their power extends 
beyond merely highlighting a problem, as they also leverage 
assumed health interventions along with them. What happens 
far less frequently, with important exceptions41,66, is the transfer 
of skills necessary to produce these estimates on a much more 
local level and investment in vital registration systems and health 
information systems67,68.
When numbers are called upon to “speak for” the health 
needs and priorities of populations in the global South, we must 
also ask the question of who produces these numbers, their 
apparent apolitical neutrality, and the broader governance struc-
tures that allow for them to hold the power they do. This does not 
mean that these estimates should not be produced, as global 
burden of disease estimates are an important “first pass” of the 
health profiles of different countries. However, they cannot be 
proxies for suffering in and of themselves, and global health 
benefits greatly from the visibility of the scientific and meth-
odological conflicts that are at the heart of tensions between 
the two sets of powerful health estimates produced by WHO 
and by IHME. Ultimately, more work needs to be done to create 
evidence that is relevant and meaningful on country and district 
levels, which means shifting resources and support for quantita-
tive—and qualitative—data production, analysis, and synthesis 
to countries that are the targeted beneficiaries of such global 
health estimates.
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